TY  -  
T1  - Rivaroksabaanin kustannusvaikuttavuus varfariiniin verrattuna ei-läppäperäisen eteisvärinän aiheuttaman aivohalvauksen estossa : järjestelmällinen kirjallisuuskatsaus 
SN  -  /  
UR  - URN:NBN:fi-fe201801151370; http://hdl.handle.net/10138/199520 
T3  -  
A1  - Koivula, Teija 
A2  -  
PB  - Helsingfors universitet 
Y1  - 2017 
LA  - fin 
AB  - Atrial fibrillation is the most common sustained cardiac arythmia. It has been estimated that there will be 14 to 17 million atrial fibrillation patients in Europe by the year 2030. In Finland, there are over 50 000 atrial fibrillation patients. The prevalence of atrial fibrillation increases by age. In addition to age, people who have hearth failure, high blood pressure, coronary artery disease, valvular hearth disease, diabetes mellitus, chronic kidney disease or who suffer from obesity have i... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - cost-effectiveness; rivaroxaban; warfarin; novel oral anticoagulants; atrial fibrillation; stroke; rivaroksabaani; varfariini; uudet oraaliset antikoagulantit; eteisvärinä; aivohalvaus; kustannusvaikuttavuus; Socialfarmaci; Social Pharmacy; Sosiaalifarmasia 
N1  -   
PP  -  
ER  -